CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$40.15−0.22 (-0.54%)
Close on Nov 17, 2026Market cap $3.88BP/E –Yield –
CRISPR Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
CRISPR Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $278.15M, down 6.1% year over year. For fiscal 2025 it was $284.81M, down 8.2% from the year before. Over ten years it grew 36.6% a year on average. The highest annual figure on record is $461.65M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $284.81M | -8.2% |
| FY2024 | Dec 31, 2024 | $310.24M | -19.9% |
| FY2023 | Dec 31, 2023 | $387.33M | -16.1% |
| FY2022 | Dec 31, 2022 | $461.65M | +35.6% |
| FY2021 | Dec 31, 2021 | $340.57M | +53.8% |
| FY2020 | Dec 31, 2020 | $221.38M | +23.4% |
| FY2019 | Dec 31, 2019 | $179.36M | +57.6% |
| FY2018 | Dec 31, 2018 | $113.77M | +63.0% |
| FY2017 | Dec 31, 2017 | $69.80M | +65.3% |
| FY2016 | Dec 31, 2016 | $42.24M | +235.9% |
| FY2015 | Dec 31, 2015 | $12.57M | +731.0% |
| FY2014 | Dec 31, 2014 | $1.51M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $67.15M | -3.9% |
| Q1 FY2026 | Mar 31, 2026 | $68.57M | -5.4% |
| Q4 FY2025 | Dec 31, 2025 | $83.53M | +16.4% |
| Q3 FY2025 | Sep 30, 2025 | $58.90M | -28.3% |
| Q2 FY2025 | Jun 30, 2025 | $69.89M | -12.8% |
| Q1 FY2025 | Mar 31, 2025 | $72.48M | -4.8% |
| Q4 FY2024 | Dec 31, 2024 | $71.74M | -24.6% |
| Q3 FY2024 | Sep 30, 2024 | $82.16M | -9.4% |
| Q2 FY2024 | Jun 30, 2024 | $80.17M | -21.1% |
| Q1 FY2024 | Mar 31, 2024 | $76.17M | -23.8% |
| Q4 FY2023 | Dec 31, 2023 | $95.14M | -8.1% |
| Q3 FY2023 | Sep 30, 2023 | $90.70M | -22.2% |
| Q2 FY2023 | Jun 30, 2023 | $101.56M | -17.6% |
| Q1 FY2023 | Mar 31, 2023 | $99.94M | -15.5% |
| Q4 FY2022 | Dec 31, 2022 | $103.56M | +0.4% |
| Q3 FY2022 | Sep 30, 2022 | $116.62M | +39.7% |
| Q2 FY2022 | Jun 30, 2022 | $123.22M | +49.7% |
| Q1 FY2022 | Mar 31, 2022 | $118.25M | +67.4% |
| Q4 FY2021 | Dec 31, 2021 | $103.10M | +180.1% |
| Q3 FY2021 | Sep 30, 2021 | $83.50M | +17.6% |
| Q2 FY2021 | Jun 30, 2021 | $82.33M | +38.7% |
| Q1 FY2021 | Mar 31, 2021 | $70.62M | +30.3% |
| Q4 FY2020 | Dec 31, 2020 | $36.80M | -24.5% |
| Q3 FY2020 | Sep 30, 2020 | $71.01M | +24.0% |
| Q2 FY2020 | Jun 30, 2020 | $59.38M | +50.2% |
| Q1 FY2020 | Mar 31, 2020 | $54.19M | +60.2% |
| Q4 FY2019 | Dec 31, 2019 | $48.76M | +69.3% |
| Q3 FY2019 | Sep 30, 2019 | $57.25M | +43.8% |
| Q2 FY2019 | Jun 30, 2019 | $39.53M | +54.2% |
| Q1 FY2019 | Mar 31, 2019 | $33.82M | +73.3% |
| Q4 FY2018 | Dec 31, 2018 | $28.80M | +43.8% |
| Q3 FY2018 | Sep 30, 2018 | $39.82M | +123.1% |
| Q2 FY2018 | Jun 30, 2018 | $25.63M | +49.7% |
| Q1 FY2018 | Mar 31, 2018 | $19.52M | +31.8% |
| Q4 FY2017 | Dec 31, 2017 | $20.03M | +28.6% |
| Q3 FY2017 | Sep 30, 2017 | $17.85M | +48.1% |
| Q2 FY2017 | Jun 30, 2017 | $17.12M | – |
| Q1 FY2017 | Mar 31, 2017 | $14.81M | – |
| Q4 FY2016 | Dec 31, 2016 | $15.57M | – |
| Q3 FY2016 | Sep 30, 2016 | $12.05M | – |
See a number that looks wrong?